As of 2025-11-18, the EV/EBITDA ratio of Allergy Therapeutics PLC (AGY.L) is -22.83. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. AGY.L's latest enterprise value is 551.08 mil GBP. AGY.L's TTM EBITDA according to its financial statements is -24.14 mil GBP. Dividing these 2 quantities gives us the above AGY.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.4x - 6.2x | 4.8x |
| Forward P/E multiples | 4.9x - 5.9x | 5.2x |
| Fair Price | (2.27) - (2.67) | (2.31) |
| Upside | -126.7% - -131.5% | -127.2% |
| Date | EV/EBITDA |
| 2025-11-17 | -22.95 |
| 2025-11-14 | -22.77 |
| 2025-11-13 | -22.88 |
| 2025-11-12 | -23.16 |
| 2025-11-11 | -22.67 |
| 2025-11-10 | -23.98 |
| 2025-11-07 | -23.03 |
| 2025-11-06 | -22.88 |
| 2025-11-05 | -22.39 |
| 2025-11-04 | -22.80 |
| 2025-11-03 | -23.98 |
| 2025-10-31 | -23.42 |
| 2025-10-30 | -21.33 |
| 2025-10-29 | -22.77 |
| 2025-10-28 | -22.16 |
| 2025-10-27 | -22.18 |
| 2025-10-24 | -22.26 |
| 2025-10-23 | -22.10 |
| 2025-10-22 | -21.36 |
| 2025-10-21 | -21.38 |
| 2025-10-20 | -21.15 |
| 2025-10-17 | -21.10 |
| 2025-10-16 | -22.36 |
| 2025-10-15 | -21.61 |
| 2025-10-14 | -21.64 |
| 2025-10-13 | -21.67 |
| 2025-10-10 | -22.90 |
| 2025-10-09 | -22.23 |
| 2025-10-08 | -22.13 |
| 2025-10-07 | -21.64 |
| 2025-10-06 | -22.44 |
| 2025-10-03 | -23.03 |
| 2025-10-02 | -22.88 |
| 2025-10-01 | -22.77 |
| 2025-09-30 | -22.80 |
| 2025-09-29 | -22.82 |
| 2025-09-26 | -22.52 |
| 2025-09-25 | -22.36 |
| 2025-09-24 | -22.39 |
| 2025-09-23 | -22.41 |
| 2025-09-22 | -22.44 |
| 2025-09-19 | -22.52 |
| 2025-09-18 | -22.36 |
| 2025-09-17 | -22.13 |
| 2025-09-16 | -22.41 |
| 2025-09-15 | -22.44 |
| 2025-09-12 | -22.52 |
| 2025-09-11 | -22.36 |
| 2025-09-10 | -21.61 |
| 2025-09-09 | -21.90 |